Hormonal-Cycle Restrictions Narrowed the Oral-THC Study’s Female Sample

The oral-THC study included women using hormonal contraception or tested in the early follicular phase. Its sex comparison did not test responses across every menstrual-cycle phase.

The restriction served an experimental purpose

The authors describe limiting variation in ovarian steroids by including women under those conditions. This can reduce one source of variability in a small controlled experiment. It also makes the tested sample more specific than a general sample of all women using cannabis at unrestricted times.

Control is not a test of hormonal causation

The study reported a selected sex difference in subjective high after 10 milligrams of oral THC. It did not randomize menstrual phases, manipulate ovarian hormones or establish which hormone caused that finding. A restriction intended to stabilize a factor cannot be presented as a direct experiment proving the factor’s mechanism.

The finding needs its population boundary

The data do not define how the same participants would respond during another phase or whether hormonal contraception changes the response relative to no contraception. Other measured endpoints did not show matching sex interactions, reinforcing the need to retain the actual outcome. For a scientific opinion, the relevant description is a selected healthy population under specified hormonal conditions. It does not justify a universal female THC-sensitivity rule or an individual impairment prediction based on cycle phase.

Related analysis: the trial’s main results and limitations.

Research cited

Aghaei and colleagues (2024). Sex Differences in the Acute Effects of Oral THC: A Randomized, Placebo-Controlled, Crossover Human Laboratory Study.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

The CBD Scan Trial Used Equal Allocation Despite Planning a Two-to-One Ratio

The scan-anxiety study ultimately randomized twenty-five participants to each treatment. The paper disclosed that its original sample-size plan anticipated a two-to-one allocation instead. The discrepancy concerned the allocation ratio The central registrar inadvertently implemented a one-to-one scheme rather than the originally intended unequal ratio. Participants still underwent randomized assignment, and…

Spread the love

Read Article: The CBD Scan Trial Used Equal Allocation Despite Planning a Two-to-One Ratio

Only Six Participants Had Severe Baseline Anxiety in the CBD Scan Trial

The scan-anxiety trial stratified randomization by baseline anxiety severity, but only six participants were in its severe category. Stratification did not supply enough data for a reliable severe-anxiety subgroup analysis. The strata helped organize allocation Participants were assigned within GAD-7 categories covering mild-to-moderate and severe anxiety. Of the fifty women…

Spread the love

Read Article: Only Six Participants Had Severe Baseline Anxiety in the CBD Scan Trial

The CBD Scan-Anxiety Trial Measured Prescan Anxiety, Not Anxiety During the Scan

The trial’s acute anxiety assessment occurred after CBD dosing but generally before the scheduled cancer scan. It did not directly measure whether CBD reduced distress inside the scanner. The two timing intervals were different Participants received the study drug within 48 hours before a tumor-assessment scan. Anxiety was reassessed two…

Spread the love

Read Article: The CBD Scan-Anxiety Trial Measured Prescan Anxiety, Not Anxiety During the Scan

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us